Price Performance of Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has experienced an interesting year when it comes to its price journey. This particular company’s stock managed to reach its 1-Year High price of $2.90 on 01/29/18, but it rose to its lowest point in the past year, $0.18 on 12/26/18.
At the end of the most recent trading day, Celldex Therapeutics, Inc. closed at $0.26. The stock began the trading session at $0.26 and hit a high of $0.27. The lowest price during the trading day was $0.25.
The shares of this company, which operates in the healthcare sector, reached a trading volume of about 1,218,763 throughout the day, which was clearly lower than the average daily volume for these shares.
At the time of writing, this publicly-traded organization holds a total market value of 44.85M, with 192 employees on its payroll.
Continuing forward, if we take into consideration what stock market experts are currently saying regarding Celldex Therapeutics, Inc.(NASDAQ:CLDX), the mean rating for this stock is 2.50. How is that calculated? Well, 0 analysts have given this company a BUY rating, 1 is rated it as OUTPERFORM, 1 has recommended that investors HOLD, 0 are considering it an UNDERPERFORM and 0 have recommended that owners of these shares SELL.
A month ago, 0 analysts thought this stock was a BUY, 1 of them posted an OUTPERFORM rating, 1 analysts recommended to HOLD this stock, 0 of them provided an underperform rating and 0 rated it as a Sell.
This company’s 100-day moving average was 0.36, while its price change was posted at -0.16. Similarly, Celldex Therapeutics, Inc. (NASDAQ:CLDX) experienced a 100-day Percent movement of -38.10% with a trading volume reaching 1,693,591.
Continuing to look at similarly important data, this stock’s distance from its 200-day Simple Moving Average, or SMA 200, is -55.04% at the time of writing. This organization’s revenue over the trailing twelve months (TTM) of active operations is 11.20M, considering the fact that it was able to rack up the income of -$164.70M through that period of time.
One widely-used way of understanding a particular company’s financial strength is to take its Total Debt to Equity Ratio, also known as D/E ratio, into account – a number that is found by dividing a company’s present total liabilities by its total stockholders’ equity. This metric just illustrates how much debt an organization is using to support its assets in relation to how much its shareholder’s equity is worth. CLDX’s Total Dept/Eq ratio is sitting at 0.00 at the time of writing, while its long-term Dept/Eq ratio is 0.00
While maintaining our attention on the Technical analysis of Celldex Therapeutics, Inc. (NASDAQ:CLDX), during the last 50 days, its Raw Stochastic average was observed 35.48%, representing a downgrade from this organization’s 20-day Raw Stochastic average – which was posted 83.70%. During the last 20-days time span, this firm’s Stochastic %K was 78.29% and its Stochastic %D was noted 73.19%.
When looking deeper into the past price path that shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have taken, we can observe multiple moving trends. This particular stock’s current year-to-date (YTD) price performance is standing at 31.53%. Meanwhile, during the past six months of trading, this stock has deteriorated to -49.94%, along with a full-year performance of -90.90%. This company’s shares increased nearly 1.27% during the last 7-day stretch and up 9.37% over the last 30 days.